Dabrafenib package insert

Dabrafenib mesylate is a white to slightly colored solid with three pKas: 6.6, 2.2, and -1.5. See PACKAGE INSERT for PATIENT COUNSELING INFORMATION and Medication

with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. 2. Mekinist is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with 1. Mekinist [package insert]. East Hanover, NJ: Novartis Pharmaceutical

Monitoring drug levels may be indicated. RESOURCES. Tobramycin Package Insert Gentamicin Package Insert Amikacin Package Insert Streptomycin Package

Dose adjustment for dabrafenib below 50 mg twice daily is not recommended when used in combination with trametinib. Please refer to the dabrafenib Package Insert, Dosing and administration, for dosing instructions for treatment with dabrafenib monotherapy. The recommended dose modification schedule is provided in Table 4-2.

1Eliquis package insert 2 Pradaxa package insert 3Savaysa package insert 4 Xarelto package insert. CrCl should be based on the Cockcroft-Gault formula

Advanced melanoma, given after surgery and used with Tafinlar (dabrafenib) Metastatic non-small cell lung cancer (NSCLC) with a certain BRAF mutation, [package insert]. DailyMed. Thawer, A, et al. (2025). Management of pyrexia associated with the combination of dabrafenib and trametinib: Canadian consensus statements. Current Oncology.

Herceptin. Package insert. Genentech Inc; 2024. 2. Herzuma. Package insert. Celltrion Inc; 2024. 3. Kanjinti. Package insert. Amgen Inc

The Food and Drug Administration (FDA) has approved Tafinlar (dabrafenib) with Mekinist Tafinlar. Package insert. Novartis; 2025. Accessed Ma.

Dabrafenib (Tafinlar) package insert; Dabrafenib (Tafinlar) patient drug information (Chemocare) History of changes in FDA indication Low-grade glioma, pediatric. : FDA approved for pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.